Anthony Dimura
Psychiatric/Mental Health · Red Bank, NJNPI 1124520333
Payments from drug & device makers
Across 1,010 payments — averaging $128.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$56K
- AbbVie$33K
- Axsome Therapeutics, Inc.$19K
- Otsuka America Pharmaceutical, Inc.$16K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$775
- plus $4K from 21 others
What the payments were for
- Consulting fees$10,4888%
- Speaking & faculty fees$100,61077%
- Travel & lodging$5,7544%
- Food & beverage$13,01010%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 100 | $56,488 |
| AbbVie(2 entities) | 305 | $32,817 |
| Axsome Therapeutics, Inc. | 106 | $18,956 |
| Otsuka America Pharmaceutical, Inc. | 94 | $15,967 |
| Alkermes, Inc. | 61 | $1,059 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $775 |
| Lundbeck LLC | 57 | $626 |
| Indivior Inc. | 38 | $432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $413 |
| Braeburn Inc. | 26 | $370 |
| Neurocrine Biosciences, Inc. | 19 | $278 |
| Teva Pharmaceuticals USA, Inc. | 19 | $271 |
| Vanda Pharmaceuticals Inc. | 17 | $243 |
| Almatica Pharma LLC | 16 | $243 |
| Corium, LLC | 12 | $183 |
| Bausch Health US, LLC | 11 | $174 |
| Sunovion Pharmaceuticals Inc. | 10 | $145 |
| Idorsia Pharmaceuticals US Inc | 8 | $120 |
| Noven Therapeutics, LLC | 5 | $73 |
| E.r. Squibb & Sons, L.L.C. | 4 | $73 |
| Eisai Inc. | 5 | $71 |
| Supernus Pharmaceuticals, Inc. | 5 | $68 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Neuronetics, Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $14 |
| Sage Therapeutics, LLC | 1 | $13 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$129,933 in reported general payments places this provider in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 40 | $77,313 |
| VraylarCariprazine Hcl | 51 | $73,290 |
| RexultiBrexpiprazole | 26 | $47,251 |
| CaplytaLumateperone Tosylate | 18 | $30,104 |
| BrixadiBuprenorphine | 13 | $20,792 |
| Paliperidone ErPaliperidone | 12 | $5,094 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 41 | $4,751 |
| MydayisDextroamphetamine/Amphetamine | 13 | $4,500 |
| ViibrydVilazodone Hcl | 12 | $4,277 |
| Divalproex Sodium ErDivalproex Sodium | 53 | $3,808 |
| Carbamazepine ErCarbamazepine | 26 | $3,732 |
| DayvigoLemborexant | 11 | $3,631 |
| Clozapine | 40 | $3,367 |
| Aripiprazole | 53 | $2,923 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 31 | $2,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $32,817 | $77,56763 claims |
| Johnson & JohnsonSpravato | $56,488 | $77,31340 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $15,967 | $47,25126 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $775 | $30,10418 claims |
| Braeburn Inc.Brixadi | $370 | $20,79213 claims |
| Eisai Inc.Dayvigo | $71 | $3,63111 claims |
| Almatica Pharma LLCSertraline Hcl | $243 | $664105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,212 psychiatric/mental health providers in New Jersey.
Other psychiatric/mental health in Red Bank
- Tony DickenRed Bank$6K
- Ubong UdofiaMarlton$407K
- Amy PinsenNewton$111K
- Aaron SpectorMarlton$100K
- Fiorella ParadisiSparta$84K
- Diane BurtBridgeton$81K
- Alta ManessHackensack$75K
- Laura LeahySewell$41K
- Linda WinfulMontclair$40K
- Marisa SavicOradel$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.